MannKind Corporation (MNKD) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

14/25

Growth 4 Margin 2 Expansion 4 Platform 1 Financial 3

latest quarter score

Earnings Reports

14
MNKD Q2 2026: Marketed Product Revenue Surges 111% as Afrezza Pediatrics and ReadyFlow Redefine Growth Mix
August 06, 2026
14
MNKD Q1 2026: Own-Brand Revenue Mix Set to Top 65% With Regulatory Catalysts Ahead
May 07, 2026
17
MannKind (MNKD) Q4 2025: Furosix Sales Surge 91% as Pediatric Afrezza and Auto-Injector Catalysts Approach
February 26, 2026
11
MNKD Q3 2025: Furo6 Doses Surge 153% as SC Pharma Integration Reshapes Growth Profile
November 05, 2025
19
MNKD Q2 2025: Blackstone $500M Facility Unlocks Pipeline Acceleration as Tivesa DPI Royalties Climb 22%
August 06, 2025
19
MannKind (MNKD) Q1 2025: Tyvaso DPI Royalties Jump 32% as Pipeline and Pediatric Catalysts Build
July 05, 2025

Browse all companies